SPOTLIGHT -
Future Direction of MS Treatment
Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD, reflect on future developments in the management of multiple sclerosis and share key advice for community physicians.
Evobrutinib in MS: The EVOLUTION RMS I and II Trials
Thought leaders in neurology consider the role of BTK inhibitors such as evobrutinib and review the potential impact on patients with progressive multiple sclerosis.
Ublituximab for MS: The ULTIMATE I and II Trials
Experts in the management of multiple sclerosis provide key insights into the use of ublituximab in multiple sclerosis and review results of the ULTIMATE I and II trials from the AAN 2021 Annual Meeting.
Monitoring Response and Sequencing Therapies in RRMS
Enrique Alvarez, MD, PhD reviews factors to consider when monitoring response to treatment, and Lawrence Steinman, MD comments on patient- and disease-related factors that may impact therapeutic sequencing.
Selecting a High-Efficacy Therapy for RRMS
Two experts in multiple sclerosis share insights on the shared decision-making process when selecting a high efficacy therapy and emphasize the importance of disease characteristics and patient preference.
Advantages of High-Efficacy Therapy in RRMS
Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD examine some advantages associated with beginning patients on higher-efficacy therapies for relapsing/remitting multiple sclerosis.
First-Line Treatment Considerations in RRMS
Experts in the management of relapsing/remitting multiple sclerosis provide key insights on the importance of early diagnosis and treatment as well as what factors to consider when selecting therapy.
Diagnosing Clinical Subtypes of Multiple Sclerosis
Lawrence Steinman, MD discusses the role of MRI and the McDonald Criteria for the diagnosis of multiple sclerosis, and Enrique Alvarez, MD, PhD defines key differences in the presentation and prevalence of its clinical subtypes.